Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9774204 | 1.00 | NAAA (0.48) | NAAAHCAR2EPHX1ACHETSHR | |
| Water SCHEMBL16149369 | 0.98 | NAAA (0.47) | NAAAHCAR2EPHX1ACHETSHR | |
| SCHEMBL1958036 | 0.94 | NAAA (0.51) | NAAAHCAR2EPHX1ACHETSHR | |
| SCHEMBL5961663 | 0.94 | NAAA (0.51) | NAAAHCAR2EPHX1ACHETSHR | |
| SCHEMBL513362 | 0.94 | NAAA (0.51) | NAAAHCAR2EPHX1ACHETSHR | |
| SCHEMBL6288811 | 0.94 | NAAA (0.51) | NAAAHCAR2EPHX1ACHETSHR | |
| SCHEMBL1278241 | 0.94 | NAAA (0.51) | NAAAHCAR2EPHX1ACHETSHR | |
| SCHEMBL1218290 | 0.94 | NAAA (0.51) | NAAAHCAR2EPHX1ACHETSHR | |
| SCHEMBL10795013 | 0.94 | NAAA (0.51) | NAAAHCAR2EPHX1ACHETSHR | |
| SCHEMBL417321 | 0.94 | NAAA (0.51) | NAAAHCAR2EPHX1ACHETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106074548-A | Monohydrate of azaadamantane derivative | 艾伯维巴哈马有限公司 | 2016-11-09 | — | — | CN | claimed |
| CN-103554107-B | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | 艾伯维巴哈马有限公司 | 2016-08-17 | — | — | CN | claimed |
| EP-2619205-A1 | MONOHYDRATE OF AN AZAADAMANTANE DERIVATIVE | AbbVie Inc. (US) | 2013-07-31 | — | — | EP | claimed |
| CN-103180321-A | Monohydrate of azaadamantane derivative | ABBOTT LAB | 2013-06-26 | — | — | CN | claimed |
| WO-2012040404-A1 | MONOHYDRATE OF AN AZAADAMANTANE DERIVATIVE | ABBOTT LABORATORIES (US) | 2012-03-29 | — | — | WO | claimed |
| CN-101541792-A | Azaadamantane derivatives and methods of use | ABBOTT LAB (US) | 2009-09-23 | — | — | CN | claimed |
| EP-2619205-B1 | MONOHYDRATE OF AN AZAADAMANTANE DERIVATIVE | ABBVIE BAHAMAS LTD (BS) | 2017-05-17 | — | — | EP | disclosed |
| CN-106074548-A | Monohydrate of azaadamantane derivative | 艾伯维巴哈马有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-106074548-A | Monohydrate of azaadamantane derivative | 艾伯维巴哈马有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-103554107-B | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | 艾伯维巴哈马有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-9359356-B2 | Azaadamantane formate ester and process for preparing azaadamantane derivatives | ABBVIE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150166541-A1 | AZAADAMANTANE FORMATE ESTER AND PROCESS FOR PREPARING AZAADAMANTANE DERIVATIVES | ABBVIE INC. | 2015-06-18 | — | — | US | disclosed |
| EP-2619205-A1 | MONOHYDRATE OF AN AZAADAMANTANE DERIVATIVE | AbbVie Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| CN-103180321-A | Monohydrate of azaadamantane derivative | ABBOTT LAB | 2013-06-26 | — | — | CN | disclosed |
| WO-2012040404-A1 | MONOHYDRATE OF AN AZAADAMANTANE DERIVATIVE | ABBOTT LABORATORIES (US) | 2012-03-29 | — | — | WO | disclosed |
| CN-1029403-C | 2-oxo-1-oxa-8-azaspiro [4,5] decane derivatives, pharmaceutical compositions containing them and process for preparing same | RICHTER GEDEON VEGYESZET (HU) | 1995-08-02 | — | — | CN | disclosed |
| CN-1049348-A | New 2-oxo-1-oxa--8-azaspiro [4,5] decane derivative contains their pharmaceutical composition and preparation method thereof | RICHTER GEDEON VEGYESZET (HU) | 1991-02-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166541-A1 | AZAADAMANTANE FORMATE ESTER AND PROCESS FOR PREPARING AZAADAMANTANE DERIVATIVES | DHRS9, GRHPR, DECR1 | NAAA 298/4885HCAR2 233/4885EPHX1 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.